Parker JN - Search Results

1

Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors.

Shah AC, Price KH, Parker JN, Samuel SL, Meleth S, Cassady KA, Gillespie GY, Whitley RJ, Markert JM. Shah AC, et al. Among authors: parker jn. J Virol. 2006 Aug;80(15):7308-15. doi: 10.1128/JVI.00725-06. J Virol. 2006. PMID: 16840311 Free PMC article.

2

Herpesvirus vectors for therapy of brain tumors.

Cassady KA, Parker JN. Cassady KA, et al. Among authors: parker jn. Open Virol J. 2010 Jun 18;4:103-8. doi: 10.2174/1874357901004030103. Open Virol J. 2010. PMID: 20811578 Free PMC article.

3

Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12.

Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ, Markert JM. Parker JN, et al. Cancer Gene Ther. 2005 Apr;12(4):359-68. doi: 10.1038/sj.cgt.7700784. Cancer Gene Ther. 2005. PMID: 15678154

4

Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model.

Hellums EK, Markert JM, Parker JN, He B, Perbal B, Roizman B, Whitley RJ, Langford CP, Bharara S, Gillespie GY. Hellums EK, et al. Among authors: parker jn. Neuro Oncol. 2005 Jul;7(3):213-24. doi: 10.1215/S1152851705000074. Neuro Oncol. 2005. PMID: 16053696 Free PMC article.

5

Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates.

Parker JN, Pfister LA, Quenelle D, Gillespie GY, Markert JM, Kern ER, Whitley RJ. Parker JN, et al. Vaccine. 2006 Mar 6;24(10):1644-52. doi: 10.1016/j.vaccine.2005.09.051. Epub 2005 Oct 5. Vaccine. 2006. PMID: 16243413

6

Oncolytic HSV-1 for the treatment of brain tumours.

Markert JM, Parker JN, Buchsbaum DJ, Grizzle WE, Gillespie GY, Whitley RJ. Markert JM, et al. Among authors: parker jn. Herpes. 2006 Nov;13(3):66-71. Herpes. 2006. PMID: 17147910 Review.

7

Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111.

Friedman GK, Langford CP, Coleman JM, Cassady KA, Parker JN, Markert JM, Yancey Gillespie G. Friedman GK, et al. Among authors: parker jn. J Neurooncol. 2009 Nov;95(2):199-209. doi: 10.1007/s11060-009-9926-0. Epub 2009 Jun 12. J Neurooncol. 2009. PMID: 19521665 Free PMC article.

8

Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12.

Markert JM, Cody JJ, Parker JN, Coleman JM, Price KH, Kern ER, Quenelle DC, Lakeman AD, Schoeb TR, Palmer CA, Cartner SC, Gillespie GY, Whitley RJ. Markert JM, et al. Among authors: parker jn. J Virol. 2012 May;86(9):5304-13. doi: 10.1128/JVI.06998-11. Epub 2012 Feb 29. J Virol. 2012. PMID: 22379082 Free PMC article.

9

Oncolytic viral therapy of malignant glioma.

Parker JN, Bauer DF, Cody JJ, Markert JM. Parker JN, et al. Neurotherapeutics. 2009 Jul;6(3):558-69. doi: 10.1016/j.nurt.2009.04.011. Neurotherapeutics. 2009. PMID: 19560745 Free PMC article. Review.

10

HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice.

Parker SD, Rottinghaus ST, Zajac AJ, Yue L, Hunter E, Whitley RJ, Parker JN. Parker SD, et al. Among authors: parker jn. Vaccine. 2007 Sep 17;25(37-38):6764-73. doi: 10.1016/j.vaccine.2007.06.064. Epub 2007 Jul 27. Vaccine. 2007. PMID: 17706843 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

47 results

Search Page

Filters